Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats

International Journal of Obesity

Volumn 28, Issue 2, 2004, Pages 211-221

  Bickel, M ^a   Gossel, M ^a   Geisen, K ^a   Jaehne, G ^a   Lang, H J ^a   Rosenburg, R ^a   Sandow, J ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Analysis of feeding behavior; Gastric emptying; HMR1426; Rodents; Sham feeding

Indexed keywords

ANOREXIGENIC AGENT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; GW 5824; HMR 1426; THYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CALCULATION; CANNULA; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; FOOD PREFERENCE; GLUCOSE TOLERANCE TEST; IC 50; MALE; MICROANALYSIS; MILK; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM FEEDING; STOMACH EMPTYING;

ANIMALIA; FISTULA; RODENTIA;

EID: 1242306691     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802540     Document Type: Article

References (26)

1. Mokdad Ali HM, Serdula MK, Dietz WH, Bowmann BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States 1991-1998. JAMA 1998; 282: 1519-1522.
2. Wolf AM, Colditz GA. Current estimates of the economic costs of obesity in the United States. Obesity Res 1998; 6: 97-106.
3. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficay and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998; 22: 32-38.
4. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124.
5. Lucas KH, Kaplan-Machlis B. Orlistat: a novel weight loss therapy. Ann Pharmacother 2001; 35: 314-328.
6. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppescharr HP, Krempf M. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight gain in obese patients. European Orlistat Study Group, Lancet 1998; 352: 167-172.
7. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocrine Rev 1999; 20: 805-875.
8. Mertens IL, Van Gaal FL. Promising new approaches to the management of obesity. Drugs 2000; 60: 1-9.
9. Chiesi C, Huppertz C, Hofbauer KH. Pharmacotherapy of obesity : targets and perspectives. Trends Pharmacol Sci 2001; 22: 247-254.
10. rd-5th June Geneva. Switzerland 1977.
11. Gossel M, Bickel M, Jaehne G, Stapf M, Wandschneider J, Sandow J. Effect of 14 days treatment with HMR1426, a new anorectically acting drug, on body weight development and obesity related serum parameters in Zucker fatty rats. Obes Res 2001; 9 (Suppl): PG72.
12. Bickel M, Jaehne G, Stapf M, Wandschneider J, Gossel M. Microstructural analysis of feeding behavior after amphetamine, sibutramine and dexfenfluramine in rats (Abstract). Int J Obes Relat Metab Disord 2000; 24 (Suppl 1): A413.
13. Reynell PC, Spray GH. The simultaneous measurement of absorption and transit in the gastrointestinal tract of the rat. J Physiol 1956; 131: 452-462.
14. Erni W, Ritschel A. Effect of temperature of perorally administered phenol red solution on gastric emptying in the rat. Arzneim Forsch/Drug Res 1977; 27: 1043-1045.
15. Droppelman DA, Gregory RL, Aplhin RS. A simplified method for assessing drug effects on gastric emptying in rats. J Pharmacol Methods 1980; 4: 227-230.
16. Asakawa A, Inui N, Ueno N, Makino S, Fujino MA, Kasuga M. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology 1999; 116: 1287-1292.
17. Kumara SA, Brawled SP, Boyd E. A permanent gastric fistula. Proc Proc Exp Biol Med 1963; 112: 451-453.
18. Sachs L. Angewandte Statistik, 4th Ed Springer-Verlag: Heidelberg, Germany; 1974.
19. Stricker-Krongrad A, Burlet C, Souquet, AM, Courcier S. Sibutramine effects on feeding behavior: a dose-dependency and microstructural analysis. Obesity Res 1995; 3 (Suppl. 4) Abstract 631.
20. Cerep. (Cell Biology & Receptorology), 128 rue DANTON, 92506 RUEIL-MAIMAISON, France (report: #91) and NOVASCREEN, 7170 Standard Drive, Hanover, Maryland, USA, 21076 (report: T/O 98-3872/3871), 1999-2001. Data on file: Aventis Pharma Deutschland GmbH, D-65926 Frankfurt (M), Germany.
21. Fink H, Rex A, Voits M. Major biological actions of CCK: a critical evaluation of research findings. Exp Brain Res 1998; 123: 77-83.
22. Miller LJ. Gastrointestinal hormones and receptors. In: Yamada T (ed). Textbook of gastroenterology, Vol 1 Lippincott Williams & Wilkins, New York; 1999. pp 35-68.
23. Hill DR, Singh L, Boden P, Pinnock R, Woodruf GN, Hughes J. Detection of CCK receptors in the CNS. In. Dourish CT, Cooper SJ, Iversen SD, Iversen 11 (Eds). Multiple chloecystokinin receptors in the CNS, Chapter 5 Oxford University Press, Oxforf, UK; 1992. pp 57-76.
24. Henke RB, Willson TM, Sugg EE, Croom DK, Dougherty RW, Queen KL, Birkemo LS, Ervin GN, Grizzle MK, Johnson MF, James MK. 3-(1H-Indazol-3-ylmethyl)-1,5- benodiazepines : CCK-A agonists that demonstrate oral activity as satiety agents. J Med Chem 1996; 39: 2655-2658.
25. Hirst CG, Aquino C, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke RB, James MK, Johnson MF, Momtahan T, Queen KL, Sherrill RG, Szewcyk J, Willson TM, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity: Optimisation of the C3 amino substituent. J Med Chem 1996; 39: 5236-5245.
26. Bignon E, Alonso, R, Arone M, Boigerain R, Brodin R, Geudet C, Heaulme M, Keane P, Landi M, Molimars J-C, Olliero D, Poncelet M, Seban E, Simiand J, Soubrie P, Pascal M, Maffrand J-P, Le Fur G. SR 146131, A new potent, orally active, and selective non-peptide cholecystokinin subtype 1 receptor agonist. II: In vivo pharmacological characterization. J Pharmacol Exp Ther 1999; 289: 752-761.